30 December 2005

Cyprotex announces a trading update for 2005

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces a trading update for 2005.

While the Company has been successful in reaching its objectives in 2005, including the establishment of a major contract with Sepracor and exceeding the Directors' expectations with respect to most of its growth targets, Cyprotex has experienced a deferment of approximately two months' revenue arising from the slower than expected initiation of the Sepracor contract it secured in August 2005. As a result, this revenue will now be recognised in 2006 and the Company now expects full year revenue for 2005 to be around GBP 2.7 million compared with GBP 2.1 million in 2004.

Each of the six key objectives for the period, as identified in the Chairman's statement for 2004, were achieved. Business expansion, both in terms of numbers of clients and scale of collaborations, has met with Directors' expectations. Cyprotex now has key customer relationships in the three global territories where opportunities for high-throughput pharmacokinetic profiling are concentrated and continues its planned expansion.

Based on order backlog, the Directors expect 2006 to start strongly. The Company's new laboratory expansion completed in 2005, together with the adoption of new technologies and products, is expected to accommodate such demands and build upon Cyprotex's reputation with its customers for innovation and 'best-in-class' quality of service.

The major contract with Sepracor demonstrates the technical benefits of international partnering with Cyprotex. This working relationship is now providing significant forward visibility for both parties, which Cyprotex now hopes to replicate through a major new signing presently being completed in Japan.

Commenting on the trading update, Robert Morrisson Atwater, Chief Executive Officer of Cyprotex PLC, said: "This delay in revenues from the Sepracor contract, although impacting on 2005, gives further visibility to revenues in 2006. Cyprotex looks forward to continued growth in the coming year."



For further information:

Cyprotex PLC
Robert Morrisson Atwater, Chairman & Chief Executive Officer
Tel: +44 (0) 1625 505 152
ir@cyprotex.com
www.cyprotex.com

Code Securities
Charles Walker
Tel: +44 (0) 20 7776 1200
cew@codesecurities.com
www.codesecurities.com

Media Enquires:

Abchurch Communications
Heather Salmond / Chris Lane
Tel: +44 (0) 20 7398 7700
chris.lane@abchurch-group.com
www.abchurch-group.com